Shareholder Class Action
SAN FRANCISCO — Directors are selling Relypsa pharmaceuticals too cheaply through an unfair process, for $32 a share or $1.5 billion, shareholders claim in Federal Court.
SAN FRANCISCO — Directors are selling Relypsa pharmaceuticals too cheaply through an unfair process, for $32 a share or $1.5 billion, shareholders claim in Federal Court.